Cutting Off Escape Routes: A Trimeric Dual-Targeting CAR Takes Aim at Multiple Myeloma

In a study published in Blood Advances, a team led by Marcela Maus from the Massachusetts General Hospital Cancer Center and Harvard Medical School utilized IsoPlexis’ Functional Proteomics to present a receptor design that enhances binding to antigens commonly present on malignant B cells.

Your data is secure

We keep your personal information safe and do not share it with any third parties. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy. You may unsubscribe at any time.

What's Inside

In this we discuss:

Combatting antigen loss
In vitro characterization confirmed by in vivo testing
Assessing CAR-T cell durability and adaptability with functional single-cell proteomics
A Deeper Look

More about this

The Need for Continued CAR Development

Cancer progression relies on escaping the immune system.

To counter this, scientists developed custom-engineered chimeric antigen receptors (CARs) to improve the effectiveness of therapeutic attempts to track and eliminate cancer cells. However, immune evasion still causes significant disease resistance and relapse.

In response to these challenges, A. Schmidt et al. leveraged IsoPlexis’ Single-Cell Functional Proteomics to create a new CAR capable of binding multiple antigens.

Download this Paper Summary to learn more!

awards-bar-3-wide-color-right
awards-bar-4-wide-color-left
Get the